Program
Anti-SIRPa Monoclonal Antibody BI 770371
Its studies are mostly in Squamous Cell Carcinoma of Head and Neck · Fatty Liver, led by Boehringer Ingelheim.
Drug pageAnti-SIRPa Monoclonal Antibody BI 770371: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.Furthest: phase 2, since Nov 4, 20244 company-led studies, 3 open or runningNext primary completion: Aug 31, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 43 open or running | phase 2since Nov 4, 2024 | Sep 19, 2021 | Aug 31, 2027phase 1 · NCT06806852 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 19, 2021First study: phase 1 study in CarcinomaFirst studyNCT05068102 · 14 enrolled · Netherlands
- Apr 8, 2022Phase 1 study in Solid TumorsNCT05327946 · 42 enrolled · United States, Canada, Japan
- Nov 4, 2024Phase 2 study in Compensated Liver CirrhosisNCT06675929 · 28 enrolled · United States
- Jan 28, 2025Phase 1 study in Squamous Cell Carcinoma of Head and NeckNCT06806852 · 91 enrolled · United States, Australia, Brazil and more
Ahead
- Aug 31, 2027Primary completion: phase 1 study in Squamous Cell Carcinoma of Head and NeckNCT06806852
TargetBeta
SIRPA →read by rule
“An immunoglobulin G1 (IgG1) monoclonal antibody targeting human signal-regulatory protein alpha (SIRPa; CD172a), ”NCIt, by rule
Other programs on SIRPA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-SIRPa Monoclonal Antibody DS-1103rule | Daiichi Sankyo | phase 2 | 2 |
| Anti-SIRPalpha Monoclonal Antibody BYON4228rule | byondis-b-v | phase 1 | 2 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06806852Squamous Cell Carcinoma of Head and Neck · United States, Australia, Brazil and more | 1 | Active, not recruiting | Aug 31, 2027 | 91 |
| NCT06675929Compensated Liver Cirrhosis · United States | 2 | Completed | Jan 13, 2026 | 28 |
| NCT05327946Solid Tumors · United States, Canada, Japan | 1 | Active, not recruiting | Jul 16, 2024 | 42 |
| NCT05068102Carcinoma · Netherlands | 1 | Active, not recruiting | Jan 22, 2026 | 14 |
How it is read
Names in the registry
- “BI 770371”, 4 entries
Conditions, from the studies’ own filings
- Squamous Cell Carcinoma of Head and Neck, 2 studies
- Fatty Liver, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.